BioCentury
ARTICLE | Company News

ThromboGenics, Novartis sales and marketing update

April 22, 2013 7:00 AM UTC

ThromboGenics said Novartis' Alcon Inc. unit launched Jetrea ocriplasmin in the U.K. to treat vitreomacular traction, including when associated with a macular hole of 400 µm or less in diameter. The launch triggered a €45 million ($58.8 million) milestone payment to ThromboGenics from Alcon under a March deal granting Alcon ex-U.S. commercialization rights to the drug. The company said the European wholesale acquisition cost of the product will be similar to the U.S. price of $3,950 for a single-use vial of 0.125 mg diluted solution for intravitreal injection - the recommended dose - but declined to disclose a U.K. price. The next launch will be in Germany. The European Commission approved the product last month. The U.K.'s NICE is reviewing Jetrea under a single technology appraisal, with a decision expected in 4Q13 (see BioCentury, March 18). ...